Value-based arrangements may be more prevalent than assumed

To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation. Surveys were administered to a convenience sample of subject matter experts who were senior representati...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of managed care Vol. 25; no. 2; pp. 70 - 76
Main Authors Mahendraratnam, Nirosha, Sorenson, Corinna, Richardson, Elizabeth, Daniel, Gregory W, Buelt, Lisabeth, Westrich, Kimberly, Qian, Jingyuan, Campbell, Hilary, McClellan, Mark, Dubois, Robert W
Format Journal Article
LanguageEnglish
Published United States MultiMedia Healthcare Inc 01.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation. Surveys were administered to a convenience sample of subject matter experts who were senior representatives from payer organizations and biopharmaceutical manufacturers. These data were supplemented with qualitative interviews in a subsample of survey respondents. Descriptive statistics, including percentages for categorical values and mean (SD) and median (interquartile range) for continuous variables, were assessed for quantitative questions. Trained reviewers collated responses to free-text survey questions and the qualitative interviews to identify themes. Of the 25 respondents, 1 manufacturer and 4 payers reported not having explored or negotiated any VBAs. Subsequently, questionnaire results from 11 biopharmaceutical manufacturers and 9 payers who had experience with VBAs were analyzed. More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of VBAs as a coverage and payment tool is increasing, VBA implementation is relatively low, with manufacturers and payers reporting that approximately 33% and 60% of early dialogues translate into signed VBA contracts, respectively. Respondents' reasoning for VBA negotiation process breakdowns generally differed by sector and reflected each sector's respective priorities. This study reveals that the majority of VBAs are not publicly disclosed, which could underestimate their true prevalence and impact. Given the effort required to implement a VBA, future arrangements would likely benefit from a framework or other evaluative tool to help assess VBA pursuit desirability and guide the negotiation and implementation process.
AbstractList OBJECTIVESTo better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation. STUDY DESIGNSurveys were administered to a convenience sample of subject matter experts who were senior representatives from payer organizations and biopharmaceutical manufacturers. These data were supplemented with qualitative interviews in a subsample of survey respondents. METHODSDescriptive statistics, including percentages for categorical values and mean (SD) and median (interquartile range) for continuous variables, were assessed for quantitative questions. Trained reviewers collated responses to free-text survey questions and the qualitative interviews to identify themes. RESULTSOf the 25 respondents, 1 manufacturer and 4 payers reported not having explored or negotiated any VBAs. Subsequently, questionnaire results from 11 biopharmaceutical manufacturers and 9 payers who had experience with VBAs were analyzed. More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of VBAs as a coverage and payment tool is increasing, VBA implementation is relatively low, with manufacturers and payers reporting that approximately 33% and 60% of early dialogues translate into signed VBA contracts, respectively. Respondents' reasoning for VBA negotiation process breakdowns generally differed by sector and reflected each sector's respective priorities. CONCLUSIONSThis study reveals that the majority of VBAs are not publicly disclosed, which could underestimate their true prevalence and impact. Given the effort required to implement a VBA, future arrangements would likely benefit from a framework or other evaluative tool to help assess VBA pursuit desirability and guide the negotiation and implementation process.
To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation. Surveys were administered to a convenience sample of subject matter experts who were senior representatives from payer organizations and biopharmaceutical manufacturers. These data were supplemented with qualitative interviews in a subsample of survey respondents. Descriptive statistics, including percentages for categorical values and mean (SD) and median (interquartile range) for continuous variables, were assessed for quantitative questions. Trained reviewers collated responses to free-text survey questions and the qualitative interviews to identify themes. Of the 25 respondents, 1 manufacturer and 4 payers reported not having explored or negotiated any VBAs. Subsequently, questionnaire results from 11 biopharmaceutical manufacturers and 9 payers who had experience with VBAs were analyzed. More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of VBAs as a coverage and payment tool is increasing, VBA implementation is relatively low, with manufacturers and payers reporting that approximately 33% and 60% of early dialogues translate into signed VBA contracts, respectively. Respondents' reasoning for VBA negotiation process breakdowns generally differed by sector and reflected each sector's respective priorities. This study reveals that the majority of VBAs are not publicly disclosed, which could underestimate their true prevalence and impact. Given the effort required to implement a VBA, future arrangements would likely benefit from a framework or other evaluative tool to help assess VBA pursuit desirability and guide the negotiation and implementation process.
Objectives: To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act as barriers to their implementation. Study Design: Surveys were administered to a convenience sample of subject matter experts who were senior representatives from payer organizations and biopharmaceutical manufacturers. These data were supplemented with qualitative interviews in a subsample of survey respondents. Methods: Descriptive statistics, including percentages for categorical values and mean (SD) and median (interquartile range) for continuous variables, were assessed for quantitative questions. Trained reviewers collated responses to free-text survey questions and the qualitative interviews to identify themes. Results: Of the 25 respondents, 1 manufacturer and 4 payers reported not having explored or negotiated any VBAs. Subsequently, questionnaire results from 11 biopharmaceutical manufacturers and 9 payers who had experience with VBAs were analyzed. More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of VBAs as a coverage and payment tool is increasing, VBA implementation is relatively low, with manufacturers and payers reporting that approximately 33% and 60% of early dialogues translate into signed VBA contracts, respectively. Respondents' reasoning for VBA negotiation process breakdowns generally differed by sector and reflected each sector's respective priorities. Conclusions: This study reveals that the majority of VBAs are not publicly disclosed, which could underestimate their true prevalence and impact. Given the effort required to implement a VBA, future arrangements would likely benefit from a framework or other evaluative tool to help assess VBA pursuit desirability and guide the negotiation and implementation process.
Author Qian, Jingyuan
Sorenson, Corinna
Dubois, Robert W
Mahendraratnam, Nirosha
Daniel, Gregory W
Richardson, Elizabeth
McClellan, Mark
Buelt, Lisabeth
Westrich, Kimberly
Campbell, Hilary
Author_xml – sequence: 1
  givenname: Nirosha
  surname: Mahendraratnam
  fullname: Mahendraratnam, Nirosha
– sequence: 2
  givenname: Corinna
  surname: Sorenson
  fullname: Sorenson, Corinna
– sequence: 3
  givenname: Elizabeth
  surname: Richardson
  fullname: Richardson, Elizabeth
– sequence: 4
  givenname: Gregory W
  surname: Daniel
  fullname: Daniel, Gregory W
– sequence: 5
  givenname: Lisabeth
  surname: Buelt
  fullname: Buelt, Lisabeth
– sequence: 6
  givenname: Kimberly
  surname: Westrich
  fullname: Westrich, Kimberly
– sequence: 7
  givenname: Jingyuan
  surname: Qian
  fullname: Qian, Jingyuan
– sequence: 8
  givenname: Hilary
  surname: Campbell
  fullname: Campbell, Hilary
– sequence: 9
  givenname: Mark
  surname: McClellan
  fullname: McClellan, Mark
  email: mark.mcclellan@duke.edu
  organization: Duke-Margolis Center for Health Policy, 1201 Pennsylvania Ave, Ste 500, Washington, DC 20004. Email: mark.mcclellan@duke.edu
– sequence: 10
  givenname: Robert W
  surname: Dubois
  fullname: Dubois, Robert W
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30763037$$D View this record in MEDLINE/PubMed
BookMark eNpdkE1LxDAQhoOsuB_6F6TgxUshmaT5wJMsfsGCF_VaJtup7tKmNWmF_fdWXC-eZhgeXp55l2wWukAnbCGc1DloB7Np59bmHEDN2TKlPedSW6XP2FxyoyWXZsFu3rAZKfeYqMowRgzv1FIYUtbiIfOUtV2krI_0hc10zoYPDBmmNLZUnbPTGptEF8e5Yq_3dy_rx3zz_PC0vt3kPUg35M5q74UqsEYjNK-AO5RFXWyt8VjrAqQyVLjJx4PyBqE2lVIaVcXRqELIFbv-ze1j9zlSGsp2l7bUNBioG1MJAE5wLtwPevUP3XdjDJNdCcIaJwCsmqjLIzX66Y-yj7sW46H8q0V-A2fPXsA
ContentType Journal Article
Copyright Copyright Intellisphere, LLC Feb 2019
Copyright_xml – notice: Copyright Intellisphere, LLC Feb 2019
DBID CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1936-2692
EndPage 76
ExternalDocumentID 30763037
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
04C
169
1CY
1KJ
23M
2KS
2WC
36B
44B
53G
5GY
6J9
6PF
7RV
7WY
7X7
8C1
8FI
8FJ
8FL
8G5
AAWTL
ABDBF
ABUWG
ACGFO
ACHQT
ADBBV
AENEX
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAW
BAWUL
BENPR
BEZIV
BMSDO
BNT
C1A
CCPQU
CGR
CUY
CVF
DIK
DWQXO
E3Z
EAP
EAS
EBS
ECM
ECT
EIF
EIHBH
EJD
EMK
EMOBN
ESX
F5P
FRNLG
FYUFA
GNUQQ
GUQSH
GX1
HMCUK
IAO
IHR
INH
INR
ITC
M0C
M0T
M2O
NAPCQ
NPM
OK1
OMK
P2P
P6G
PQBIZ
PQBZA
PQQKQ
SJN
TR2
U5U
UKHRP
ZGI
K9.
7X8
ID FETCH-LOGICAL-p239t-986bb145afa7160d209a35f5c87baf652347e59303b24b7a2f7d446a4d0a74513
ISSN 1088-0224
IngestDate Fri Apr 12 01:00:30 EDT 2024
Thu Oct 10 19:31:03 EDT 2024
Thu May 23 23:44:55 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p239t-986bb145afa7160d209a35f5c87baf652347e59303b24b7a2f7d446a4d0a74513
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 30763037
PQID 2187912284
PQPubID 105486
PageCount 7
ParticipantIDs proquest_miscellaneous_2229100191
proquest_journals_2187912284
pubmed_primary_30763037
PublicationCentury 2000
PublicationDate 2019-02-00
20190201
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: 2019-02-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Jamesburg
PublicationTitle The American journal of managed care
PublicationTitleAlternate Am J Manag Care
PublicationYear 2019
Publisher MultiMedia Healthcare Inc
Publisher_xml – name: MultiMedia Healthcare Inc
SSID ssj0036846
Score 2.4044523
Snippet To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their success or act...
Objectives: To better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their...
OBJECTIVESTo better understand the prevalence of US value-based payment arrangements (VBAs), their characteristics, and the factors that facilitate their...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 70
SubjectTerms Drug Industry - economics
Drug Industry - organization & administration
Drug Industry - statistics & numerical data
Health administration
Humans
Insurance, Health - economics
Insurance, Health - organization & administration
Insurance, Health - statistics & numerical data
Interviews as Topic
Payment systems
Pharmaceuticals
Polls & surveys
Qualitative research
Surveys and Questionnaires
United States
Value-Based Purchasing - statistics & numerical data
Title Value-based arrangements may be more prevalent than assumed
URI https://www.ncbi.nlm.nih.gov/pubmed/30763037
https://www.proquest.com/docview/2187912284
https://search.proquest.com/docview/2229100191
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBVNToVS-t1t0qBCb8FlrU-LnLIhaShJCq237M1IK5k9BCe4u4fm12fGsr02NKXtxRjZWLt-8mg0em-GkI-ZYxy8iDLx0giU5LDEeCeTMM00WyqxNE1M9_JKnc_Fl4VcbMulNuqStfu0vPutruR_UIU2wBVVsv-AbP9QaIBzwBeOgDAc_wrjH_Z6E5IZTET-8LiuUScQFWuX9tfhDD_YOiDJAvrELf98BR8z4AHmaFSeM9-qS6phKonIbPVN9upt5HoVKl9jwvCqG0sw0a566_4d-uwEZSfI7qv6S99GGq8hoawNlqPafSCcieS_LiaBMqgRv6PRDuNGUyemalhsI2JnCtYtQf8hzkOxzXCVMGVG1jnKottRyAamNtYbGWfQvvpanM0vLor8dJHvkB2eIsnz86In_XCVRb1Z1_vD64rGv8ifkaftwoAeR5Sfk0ehekGexKgqjf_vJTkaIE6HiFNAnM4CRcRpjzhFxGmL-CsyPzvNT86TtvxFcsu4WScmU86lQtrSwqJ26tnUWC5Lucy0s6WSjAsdpAEfxDHhtGWl9rC4t8JPrRYy5a_JbnVThbeEqkxKHVLhuMIS4zzTPstSqV0pmOfGTch-9xqKdpj9LBgWok8Z-C8T8qG_DNYHt5RsFW42cA9jBrN4mXRC3sTXV9zGNCkFzB4Kfpx-9-eH75HH2yG0T3bX9Sa8B0dv7Q4a7O4BfNFXpw
link.rule.ids 315,786,790
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Value-Based+Arrangements+May+Be+More+Prevalent+Than+Assumed&rft.jtitle=The+American+journal+of+managed+care&rft.au=Mahendraratnam%2C+Nirosha&rft.au=Sorenson%2C+Corinna&rft.au=Richardson%2C+Elizabeth&rft.au=Daniel%2C+Gregory+W&rft.date=2019-02-01&rft.pub=MultiMedia+Healthcare+Inc&rft.issn=1088-0224&rft.eissn=1936-2692&rft.volume=25&rft.issue=2&rft.spage=70&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1088-0224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1088-0224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1088-0224&client=summon